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Objective: The aim of this study is to establish lipoprotein-associated phospholipase A2 (Lp-PLA2) reference
intervals (RIs) in healthy Chinese Han adults as a clinical diagnostic indicator according to the Clinical and
Laboratory Standards Institute (CLSI) C28-A3 guidelines.
Design and methods: Lp-PLA2 levels in 763 healthy Chinese Han subjects (392 males and 371 females) were
determined by colorimetric analysis and the central 95th percentile RIs were determined using non-parametric
statistical methods. The correlations between serum Lp-PLA2 and blood markers were analyzed by Spearman
correlation analyses.
Results: The Lp-PLA2 levels showed a Gaussian distribution with a statistically significant difference between
females and males (t = 4.866, P < 0.001). The RIs of serum Lp-PLA2 were 194–640 U/L (18–49 years) and 208–698
U/L (50–88 years) for females, and 230–728 U/L for males. There was a positive correlation between Lp-PLA2 levels
and age, Body Mass Index (BMI), as well as with levels of alanine aminotransferase (ALT), gamma-glutamyltransferase
(GGT), total bilirubin (TBIL), triglyceride (TG), total cholesterol (Tch), low density lipoprotein cholesterol (LDL-c),
apolipoprotein B (apoB), glucose (Glu), high sensitivity C reactive protein (Hs-CRP), white blood cell (WBC), hemoglobin
(HGB) and red blood cell (RBC) (P < 0.05). A negative correlation was found with high density lipoprotein cholesterol
(HDL-c) and Apolipoprotein AI (apoAI), and no correlation was found with platelet (Plt) levels.
Conclusion: Our results establish the RIs of serum Lp-PLA2 in healthy Chinese Han adults and demonstrate correlations
between serum Lp-PLA2 and age, BMI, ALT, GGT, TBIL, TG, Tch, HDL-c, LDL-c, apoAI, apoB, Glu, Hs-CRP, WBC, RBC, and
HGB levels.
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Lipoprotein-associated phospholipase A2 (Lp-PLA2), also
known as plasma platelet-activating factor acetylhydrolase
(PAF-AH), is a Ca2+-independent enzyme and a member
of the phospholipase A2 superfamily [1]. Lp-PLA2 hy-
drolyzes platelet-activating factor (PAF) and oxidizes
phospholipids with a modified short fatty acyl chain
esterified at the Sn-2 position [2]. Many studies have indi-
cated that Lp-PLA2 is an independent predictor for
cardiovascular disease (CAD), with elevated Lp-PLA2 ac-
tivity associated with an increased risk for CAD [3-5].
Additionally, Lp-PLA2 levels have been implicated in
atherosclerotic plaque formation [6], inflammatory bowel* Correspondence: chenyu_zyyy@163.com
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stated.disease [7], acute respiratory distress syndrome [8] and se-
vere anaphylaxis [9].
Brilakis et al. [10] revealed that Lp-PLA2 activity and
mass are independently influenced by race and gender.
The largest ethnic group both in China and the world is
the Chinese Han, and therefore related studies investi-
gating the activity distribution of Lp-PLA2 in this popu-
lation will be of great significance and pave the way for
clinical diagnosis and study. Reference intervals of Lp-
PLA2 levels are an important parameter for the clinical
evaluation of patient health. To the best of our know-
ledge, there have been no relevant published studies
defining Lp-PLA2 reference intervals (RIs) in the Han
population of China. This study establishes the RIs ac-
cording to the recommendations of the CLSI C28-A3d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Lp-PLA2 and blood markers in healthy Han adults [11].
Materials and methods
Study population
In this study, 763 adults of Han ethnicity from Zhejiang
province in Eastern China who were attending their an-
nual health examination in the healthcare center of the
First Affiliated Hospital of Zhejiang University were re-
cruited as subjects. The health status of these partici-
pants was determined by a self-report questionnaire.
Of the 763 subjects, 392 were males between the ages
of 18–87 years (mean: 57.4 years) and 371 were females
between 18–88 years (mean: 53.0 years). All participants
met the following requirements: no history of cardiovas-
cular disease or diabetes mellitus, not taking lipid-
lowering drugs, not taking corticosteroids, triglyceride
level below 1.70 mmol/L, total cholesterol level below
5.70 mmol/L, low density lipoprotein cholesterol (LDL-c)
level below 3.61 mmol/L, high density lipoprotein cho-
lesterol (HDL-c) above 0.91 mmol/L, fasting blood glucose
level below 6.16 mmol/L and normal liver and kidney
function. The standards above, excluding populations ma-
nifesting abnormal blood lipids that are an important risk
factor for atherosclerotic cardiovascular disease, are out-
lined in the ‘Guidelines on Prevention and Treatment of
Blood Lipid Abnormality’ established by the Special Group
on Prevention and Treatment of Blood Lipid Abnormality
affiliated with the Chinese Journal of Cardiology [12].
This study was approved by the Ethics Committee of
the First Affiliated Hospital, College of Medicine, Zhejiang
University, and written informed consent was obtained
from each individual.
Sample collection
Venous blood was collected from subjects in a state of
quiet and fasting. Serum samples were obtained by cen-
trifugation within 2 hours of initial collection, and stored
at - 80°C for processing. Routine analyses of blood sam-
ples were completed on the same day.
Lp-PLA2 assay
Serum samples were tested using a Hitachi 7600 auto-
matic biochemical analyzer (Hitachi Ltd., Tokyo, Japan)
equipped with an Azwell Auto PAF-AH kit (Azwell Inc.,
Osaka, Japan). According to colorimetry methods previ-
ously reported by Kosaka et al. [13], the activity of
Lp-PLA2 was detected based on the principle that it
catalytically hydrolyzes the Sn-2 position of the substrate
1-myristoyl-2-(4-nitrophenylsuccinyl) phosphatidylcholine
and produces 4-nitrophenyl succinate which is immedi-
ately degraded to 4-nitrophenol in an aqueous solution,
which can be detected at an absorbance reading of
405 nm.Biochemical and blood cell count assays
Alanine aminotransferase (ALT), gamma-glutamyltransferase
(GGT), total bilirubin (TBIL), triglyceride (TG), total chol-
esterol (Tch), high density lipoprotein cholesterol (HDL-c),
low density lipoprotein cholesterol (LDL-c), apolipoprotein
AI (ApoAI), apolipoprotein B (apoB), glucose (Glu), and
high sensitivity C reactive protein (Hs-CRP) levels were
measured with a Hitachi 7600 automatic biochemical
analyzer using Roche reagents (Roche Diagnostics,
Mannheim, Germany) for ALT, GGT, TBIL, TG, Tch and
Glu, and using SSUF reagents (SSUF, Shanghai, China) for
Hs-CRP, LDL-c, HDL-c, apoAI and apoB. White blood
cell (WBC), red blood cell (RBC), and platelet (Plt) levels
were measured using the XE-2100 automated hematology
analyzer (Sysmex, Kobe, Japan) with Sysmex reagents
(Sysmex, Kobe, Japan).
Statistical analysis
All the experimental data was statistically analyzed using
SPSS 13.0 software. The reference intervals acquired are
expressed as medians and percentiles. Statistical methods
recommended by the CLSI C28-A3 document were used
to define the RIs [11]. The recommended nonparametric
central 95th percentile intervals were used to define the
RIs for their simplicity and reliability [11]. One-sample
Kolmogorov-Smirnov tests were used for assessing nor-
mality of Lp-PLA2 level distributions and one-way ana-
lyses of variance (ANOVA) were used for comparisons
across different groups. Outliers in the selected data were
detected by means of the Dixon outlier range statistic
[11,14]. For comparison between gender groups, Student’s
t-tests were used, and Spearman correlation analyses were
applied for correlations between serum Lp-PLA2 and
other blood markers in the whole study population. As an
index to estimate the extent of obesity, the body-mass
index (BMI) was calculated by body weight (kg) divided by
the square of the height (m2). For all analyses, a P value
below 0.05 indicated statistical significance.
Results
Assessment of distribution normality
Table 1 showed the main characteristics of all 763
healthy Chinese Han participants. The distribution of
serum Lp-PLA2 levels in all 763 subjects was shown in
Figure 1, and the frequency profile illustrated a Gaussian
distribution (Z = 0.485, P = 0.972). When a separate statis-
tical analysis was performed by gender, a Gaussian distri-
bution for Lp-PLA2 was also manifested for each gender
(male, Z = 1.197, P = 0.114; female, Z = 0.721, P = 0.675).
Serum RIs of Lp-PLA2 based on gender and Age
Male serum Lp-PLA2 levels were significantly higher
than in females (P < 0.05). Selected participants were di-
vided into different groups according to gender and age
Table 1 Main characteristics of 763 healthy Chinese Han
participants
Variable
Age (years) 55.3 ± 15.1
Female/male 371/392
BMI (kg/m2) 22.6 ± 3.0
ALT (U/L) 18.6 ± 8.7
GGT (U/L) 23.2 ± 11.0
TBIL (μmol/L) 13.2 ± 4.9
TG (U/L) 1.07 ± 0.41
TCh (U/L) 4.21 ± 0.64
HDL-c (mmol/L) 1.31 ± 0.32
LDL-c (mmol/L) 2.44 ± 0.52
ApoAI (mmol/L) 1.19 ± 0.28
ApoB (mmol/L) 0.72 ± 0.16
fasting glucose (mmol/L) 4.79 ± 0.55
WBC (×109/L) 5.84 ± 1.47
HGB (g/L) 136.6 ± 23.1
RBC (×1012/L) 4.42 ± 0.76
Plt (×109/L) 202 ± 59
Hs-CRP (mg/L) 1.7 ± 3.9
Lp-PLA2 activity (U/L) 467 ± 127
Abbreviations: ALT alanine aminotransferase, ApoAI apolipoprotein AI, ApoB
apolipoprotein B, BMI body mass index, GGT gamma-glutamyltransferase,
HDL-c high density lipoprotein cholesterol, HGB hemoglobin, Hs-CRP high
sensitivity C reactive protein, LDL-c low density lipoprotein cholesterol, Lp-PLA2
lipoprotein-associated phospholipase A2, Plt platelet, RBC red blood cell, TBIL
total bilirubin, Tch total cholesterol, TG triglyceride, WBC white blood cell.
Figure 1 Gaussian distribution of Lp-PLA2 results. A one-sample
Kolmogorov–Smirnov test of normality indicates a Gaussian
distribution.
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Serum Lp-PLA2 levels among males in the six age
groups did not show statistically significant differences
and thus were combined into one group. However, fe-
male Lp-PLA2 levels showed statistically significant dif-
ference among the six groups (P < 0.05), and post hoc
analysis found that there were no statistically significant
differences among the three groups < 50 years or the
three groups ≥ 50 years of age and thus female partici-
pants were combined into two groups (18–49 and 50–
88 years). Nonparametric statistical methods were used
to calculate RIs with central 95th percentiles, and the
2.5th and 97.5th percentiles of serum Lp-PLA2 levels ac-
cording to gender and/or age were showed in Table 2.
Lp-PLA2 levels in females 18–49 years of age were sig-
nificantly lower than those of females 50–88 years of
age (P < 0.05).
Correlation between Lp-PLA2 and other blood markers
Spearman correlations were utilized to analyze differences
between Lp-PLA2 and other blood markers (Table 3),
which indicated that serum Lp-PLA2 levels were positively
associated with age, BMI, the levels of ALT, GGT, TBIL,
TG, Tch, LDL-c, apoB, Glu, and Hs-CRP, as well as HGB,
WBC and RBC counts (P < 0.05). Conversely, serum Lp-
PLA2 levels were negatively correlated with HDL-c and
apoAI levels (P < 0.05), and no correlation was found with
Plt counts.
Discussion
This study establishes the RIs of serum Lp-PLA2 levels
in healthy Chinese Han participants according to the
CLSI C28-A3 guidelines [11]. Furthermore, sample sizes
used in this study are in accordance with the guidelines,
which recommend a minimum of 120 subjects for each
partition group [11]. This study demonstrates gender
differences in RIs of serum Lp-PLA2 levels, with, signifi-
cantly lower serum levels in females as compared to
males (230–728 U/L), as well as a female age difference,
with females 18–49 years of age showing lower levels
those of females 50–88 years of age (194–640 and 208–




n Median Percentile of reference interval
2.5th 25th 50th 75th 97.5th
Female
18-49 145 415 194 345 415 489 640
50-88 226 462 208 388 462 542 698
Male
18-87 392 504 230 399 504 579 728
Table 3 Spearman correlation coefficients between serum
Lp-PLA2 and blood markers


















Abbreviations: ALT alanine aminotransferase, ApoAI apolipoprotein AI, ApoB
apolipoprotein B, BMI body mass index, GGT gamma-glutamyltransferase, Glu
glucose, HDL-c high-density lipoprotein cholesterol, HGB hemoglobin, Hs-CRP
high sensitivity C reactive protein, LDL-c low density lipoprotein cholesterol,
Lp-PLA2 lipoprotein-associated phospholipase A2, Plt platelet, RBC red blood
cell, TBIL total bilirubin, Tch total cholesterol, TG triglyceride, WBC white
blood cell.
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levels in female as compared to male [15,16]. Kosaka
et al. [17] reported the serum Lp-PLA2 activity for fe-
males was significantly lower than that of males at the
5% level in a healthy Japanese population, and suggested
that Lp-PLA2 activity levels were inversely proportional
to estrogen concentrations, with Lp-PLA2 activity levels
in females ≥ 50 years higher than in younger females,
similar to the results of this study.
The median levels of Lp-PLA2 in males and females in
this study were 504 U/L and 446 U/L, respectively,
which were similar to the values (male, 506 U/L; female,
439 U/L) previously reported by Winkler et al. [16]. The
low Lp-PLA2 levels observed in females may result from
the secretion of estrogen, as Lp-PLA2 levels in pre-
menopausal females were lower than those of meno-
pausal females. This estrogen effect was suggested in a
study by Yoshimura et al. [18] showing a 26% reduction
in Lp-PLA2 levels in menopausal females two weeks
after receiving estrogen replacement therapy.
Lp-PLA2 is an enzyme that mainly exists in combin-
ation with lipoprotein particles in blood circulation, with
80-85% bound to LDL, approximately 15-20% bound to
HDL [19]. Da Silva et al. analyzed the influence ofobesity on Lp-PLA2 and found that enzyme activity was
positively associated with BMI and the function of Lp-
PLA2 changes with adolescent obesity [20]. A positive
correlation also had been established between Lp-PLA2
levels and Tch, LDL-c and apoB, and a negative correl-
ation with HDL-c and apoA I, which was confirmed
by the results of this study. These data suggest that Lp-
PLA2 is present in atherogenic lipoproteins. Similarly,
the confirmation of a positive correlation with ALT,
GGT and TBIL can be associated with the secretion
of Lp-PLA2 from liver cells [21], which may be the prin-
cipal source of biliary Lp-PLA2 responsible for the ad-
justment of gastrointestinal PAF and phospholipid
metabolism [22]. Stafforini et al. found that apoB was
the factor most strongly correlated with Lp-PLA2 levels,
which manifests a strong bonding force with Lp-PLA2
due to its carboxyl terminus [23]. ApoB is a structural
protein of lipoproteins, excluding HDL-c, and plays
an important role in transporting lipids to extrahepatic
tissues and recognizing LDL receptors. Some studies in-
dicated that Lp-PLA2 induced WBC activation and in-
flammatory responses in vitro, and that this activation
may be associated with a rapid increase in circulatory
Lp-PLA2 expression [24,25]. Yoshida et al. found that
Lp-PLA2 may play an important role in scavenging oxi-
dized phospholipids in RBC membranes and in main-
taining the normal rheological properties of erythrocytes
[26]. Furthermore, Uydu et al. reported that serum Lp-
PLA2 was positively associated with the variations of
Hs-CRP in stable CAD patients and was a more reliable
indicator of coronary stenosis [27]. These findings may
help explain the positive correlations observed between
Lp-PLA2 levels and Hs-CRP, HGB, WBC, and RBC in
this study. Taken together, the data suggest that after
Lp-PLA2 is bound to LDL via apoB, lysophosphatidyl-
choline and free oxidized fatty acids, two strong pro-
inflammatory factors, are produced through the hydroly-
sis and oxidation of phospholipids, thereby promoting
chronic inflammation and atherosclerosis [28].Conclusions
Lp-PLA2 has recently attracted considerable attention
for its importance in predicting cardiovascular disease
and prognostic evaluation. In addition, Lp-PLA2 has also
been proposed as a new independent risk factor for the
development and progression of coronary heart disease
[29,30]. As a result, the establishment of a reference
interval for Lp-PLA2 levels is needed for the clinical
evaluation of patients with cardiovascular disease. More-
over, considering the influence of gender and age on Lp-
PLA2 levels, our results not only provide an alternative
reference for clinical practice, but also pave the way for
further clinical studies.
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